Development of a 177Lu-labeled EphA2-targeting cyclic peptide combined with an HPK1 inhibitor for synergistic anti-tumor effects.
Meng-Jie Zhang, Yirong Chen, Caixia Zhang...
https://pubmed.ncbi.nlm.nih.gov/41037223/Actively Recruiting
Led by First Hospital of China Medical University · Updated on 2026-05-18
30
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are investigating a new imaging agent called 68Ga-DOTA-EphA2, which targets Ephrin type-A receptor 2 EphA2, a protein found in high amounts in many solid tumors. EphA2 is linked to tumor growth, spread, and poor outcomes, but current tools to measure EphA2 in the body without surgery are limited. This study aims to develop and assess this novel tracer for use with positron emission tomography PET to better visualize EphA2-positive cancers. The study involves a single group of patients with malignant tumors undergoing PETCT imaging using the 68Ga-DOTA-EphA2 radioligand. This imaging agent is injected, and scans are performed approximately 2 to 3 hours later to observe how the tracer distributes in the body and accumulates in tumors. The research focuses on assessing safety, including any adverse events within 24 hours of injection, and measuring tracer uptake in tumors and healthy tissues. Participants will be monitored during and after the PETCT procedure with evaluations of imaging results and safety assessments. Researchers will collect data on adverse events and tracer distribution using standardized uptake values. The total involvement includes the imaging session and follow-up within 24 hours to monitor for side effects. This study is observational and aims to improve noninvasive tumor imaging methods by evaluating this new agents performance and safety.
CONDITIONS
First-in-Human Study of the Radioligand 68Ga- DOTA-EphA2
S
Shu Wang, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
First Hospital of China Medical University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 2 to 3 hours
Participants undergo PET/CT imaging with the 68Ga-DOTA-EphA2 radioligand to assess EphA2 expression in malignant tumors.
1 imaging visit (in-person)
Duration - 24 hours after tracer injection
Participants are observed for any adverse events following tracer administration.
Observation period without additional visits
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Meng-Jie Zhang, Yirong Chen, Caixia Zhang...
https://pubmed.ncbi.nlm.nih.gov/41037223/First Hospital of China Medical University
Lead Sponsor